Osi Pharmaceuticals, Inc.

Pfizer Corporation

Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbott Laboratories Corporation

Amitech Therapeutic Solutions, Inc.

Purdue Research Foundation

Cornell University

Blinkbio, Inc.

Pfizer Products Inc.

Lee Daniel Arnold

Paul Rafferty

Mark Joseph Mulvihill

Andrew Philip Crew

Heather Renee Coate

Bijoy Panicker

Douglas S Werner

Ayako Honda

David J Calderwood

Kristen Michelle Mulvihill

Jing Wang

Gavin C Hirst

Meizhong Jin

Xin Chen

James David Beard

Kam W Siu

Brian Volk

Paula A R Tavares

Apoorba Bharadwaj

Quinghua Weng

Hanqing Dong

Eric A Murphy

Neil Wishart

Han-Qing Dong

Francis Barany

Anna M Ericsson

Kurt Ritter

Radoslaw Laufer

An-Hu Li

Michael M Friedman

Donald E Bergstrom

Rainer Munschauer

Kenneth W Foreman

Yingchuan Sun

Tao Zhang

David N Johnston

Qinghua Weng

Mikel Paul Moyer

Susan Beth Sobolov-Jaynes

Anthony Innocenzo Nigro

Sarah Filippa Giardina

Maneesh Pingle

Cara Cesario

Michael J Wyle

Rodney C Schnur

Michael Michaelides

Richard W Dixon

Teresa Barlozzari

Arno G Steinig

Kevin James Doyle

Robert W Steele

Helen L Twigger

Isabel Fernandez

Yajun Xu

Michael Hockley

Allyson Turner

David J Wilkins

Stevan Wakefield Djuric

Takushi Kaneko

Jotham Wadsworth Coe

Alan Frank Gasiecki

David A Cheresh

Steven K Davidsen

Michael L Curtin

Yan Guo

Robin R Frey

James H Holms

Zhiqin Ji

Irini Akritopoulou-Zanze

Yujia Dai

John D Haley

Douglas H Steinman

Hans Wolfgang Hoeffken

Carol K Wada

Henry Q Zhang

Kevin Patrick Cusack

Zhiren Xia

Elizabeth Buck

Hormoz Mazdiyasni

Marina Moran Moset

David John Calderwood

Makoto Takeshita

Jose Maria Castellano Berlanga

Vijaya J Gracias

Melanie A Muckey

Karen Nazaretian Allen

Barbara F Scott

Jürgen Dinges

Qun-Sheng Ji

Amo G Steinig

Kimba Lee Fischer

Nancy J Bump

Cornelia Bellamacina

Beatriz Gonzalez Pascual

Jose L Ortego Martinez

Maria J Perez De Vega

Nobuhiko Iwasaki

Nobuo Ogawa

Bojuan B Deng

Gerald B Tometzki

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Monomers capable of dimerizing in an aqueous solution, and methods of using same

Described herein are silyl monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. Such multimer forming associations of monomers may be promoted by the proximal binding of the monomers to their target biomolecule(s). In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer, (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.

Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same

Provided herein are compounds useful for kinase inhibition.

Heterocyclic compounds useful for kinase inhibition

The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 &#x3bc;M and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

Coferons and methods of making and using them

The present invention is directed to methods and compositions for suppressing lymphangiogenesis, angiogenesis and/or tumor growth. The methods comprise contacting the tumor with a compound that (i) stabilizes a protein kinase in the inactive state and (ii) is not an ATP competitive inhibitor of the protein kinase in the active state.

Therapeutic methods and compositions involving allosteric kinase inhibition

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Fused bicyclic mTOR inhibitors

6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors

Methods and compositions for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially (a) a therapeutically effective amount of an anti-cancer agent and (b) an IGF1R inhibitor compound of Formula I, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. Suitable IGF1R inhibitor may be represented by Formula I: wherein X, X, X, X, X, X, X, R, and Qare defined herein.

Combination cancer therapy

Fused bicyclic motor inhibitors

Compounds of the formula  and pharmaceutically acceptable salts thereof, wherein X, X, X, X, X, X, X, R, and Qare defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

Fused bicyclic mTor inhibitors

Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

4-aminopyrrolopyrimidines as kinase inhibitors

Growing community of inventors

Westborough, MA, United States of America

Lee Daniel Arnold